Virginia Retirement Systems Et Al Akebia Therapeutics, Inc. Transaction History

Virginia Retirement Systems Et Al

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$0.72 - $2.93 $80,496 - $327,574	-111,800 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$2.26 - $3.34 $106,219 - $156,980	-47,000 Reduced 29.6%	111,800 $253,000
Q3 2021 Oct 21, 2021	BUY	$2.35 - $3.88 $240,640 - $397,312	102,400 Added 181.56%	158,800 $457,000
Q2 2021 Aug 13, 2021	BUY	$2.83 - $4.2 $27,168 - $40,320	9,600 Added 20.51%	56,400 $214,000
Q1 2021 Apr 30, 2021	BUY	$2.92 - $5.06 $77,088 - $133,584	26,400 Added 129.41%	46,800 $158,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $191,142 - $325,458	-86,100 Reduced 80.85%	20,400 $57,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $12,667 - $69,324	-5,300 Reduced 4.74%	106,500 $267,000
Q2 2020 Aug 12, 2020	SELL	$6.67 - $13.58 $272,803 - $555,422	-40,900 Reduced 26.78%	111,800 $1.52 Million
Q1 2020 May 12, 2020	BUY	$4.1 - $10.24 $565,390 - $1.41 Million	137,900 Added 931.76%	152,700 $1.16 Million
Q4 2019 Jan 27, 2020	SELL	$3.16 - $6.73 $24,332 - $51,821	-7,700 Reduced 34.22%	14,800 $94,000
Q3 2019 Oct 22, 2019	BUY	$3.55 - $5.4 $79,875 - $121,500	22,500 New	22,500 $88,000
Q2 2019 Jul 26, 2019	SELL	$4.1 - $8.05 $66,420 - $130,410	-16,200 Closed	0 $0
Q1 2019 Apr 25, 2019	BUY	$5.41 - $8.73 $13,525 - $21,825	2,500 Added 18.25%	16,200 $133,000
Q4 2018 Feb 07, 2019	BUY	$5.39 - $9.15 $73,843 - $125,355	13,700 New	13,700 $76,000
Q3 2018 Nov 02, 2018	SELL	$7.44 - $10.65 $1.05 Million - $1.5 Million	-141,100 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$9.15 - $11.34 $1.29 Million - $1.6 Million	141,100 New	141,100 $1.41 Million

110

55.3M

554K

246K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $245M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.